Novartis Zelmac Trade Name Could Be Changed Following FDA Discussions
Executive Summary
Novartis' discussions with FDA regarding use of the trade name Zelmac for the irritable bowel syndrome therapy (tegaserod) may lead to the company launching the product under a different name.
You may also be interested in...
Novartis Zelnorm DTC Ads To Start In Fall; Resources Shifted From Field Force
Novartis plans to launch a national DTC campaign for its irritable bowel syndrome agent Zelnorm early in the third quarter, the company announced during its July 21 investor conference call
Novartis Zelnorm DTC Ads To Start In Fall; Resources Shifted From Field Force
Novartis plans to launch a national DTC campaign for its irritable bowel syndrome agent Zelnorm early in the third quarter, the company announced during its July 21 investor conference call
Novartis’ Zelnorm Has 25% Adoption Rate Among Specialists After 2 Months
The uptake of Novartis' irritable bowel syndrome therapy Zelnorm will accelerate after physicians obtain more "feedback" from early users, U.S. Commercial Operations General Manager Kurt Graves said Oct. 17 during a Novartis R&D briefing in New York City